Products
Pre-Made Eflimrufusp Alfa Biosimilar, Fusion Protein targeting FGF2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BFGF/FGF-2/FGFB/HBGF-2 for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-820
Pre-Made Eflimrufusp Alfa Biosimilar, Fusion Protein targeting FGF2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BFGF/FGF-2/FGFB/HBGF-2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) play important roles in angiogenesis-related diseases. Eflimrufusp alfa is a soluble fusion protein composed of the human VEGF receptor 1 (VEGFR1) extracellular domain 2 (ECD 2), VEGFR2 ECD 3, FGFR1 ECDs 2 and 3, and the Fc regions of human immunoglobulin G1. By targeting VEGF and FGF2, RC28-E may represent a useful antiangiogenetic agent.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-820-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-820-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-820-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-820-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Eflimrufusp Alfa Biosimilar, Fusion Protein targeting FGF2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BFGF/FGF-2/FGFB/HBGF-2 |
| INN Name | Eflimrufusp Alfa |
| Target | FGF2 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - [FLT1 (fms- related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) domain 2 fragment (132-232) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF- R2, FLK1, CD309) domain 3 fragment (227-327) - FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2) domains 2 and 3 fragment (150- 361)]2 - IGHG1 Fc (Fragment constant) |
| VD LC | Fusion - [FLT1 (fms- related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor) domain 2 fragment (132-232) - KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF- R2, FLK1, CD309) domain 3 fragment (227-327) - FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2) domains 2 and 3 fragment (150- 361)]2 - IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | RemeGen, Ltd. (Shandong China) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
